Positron emission tomography in bronchioloalveolar carcinoma of the lung

T. W. Huang, L. F. Lin, C. M. Hsieh, Y. L. Cheng, H. Chang, C. Tzao, S. C. Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: This study assessed the maximum standard uptake value of positron emission tomography-computed tomography in patients of pulmonary adenocarcinoma with bronchioloalveolar carcinoma features and whether SUVmax correlates with pathological status, lymph node metastasis, and prognosis. Methods: We retrospectively reviewed 674 patients diagnosed with non-small-cell lung cancer between January 2002 and June 2009. Patients with clinical stage I-II disease underwent a preoperative PET-CT scan followed by anatomic resection. We reviewed the clinical features of 209 patients with an average follow-up of 87 months. Results: We analyzed clinical variables for 40 patients with BAC features and 169 patients without BAC features. Age, sex, location, and number of dissected lymph nodes, carcinoembryonic antigen level, and lymphovascular invasion had no difference between the two groups. Compared with non-BAC patients, patients with BAC features had a lower SUVmax (2.51 ± 2.02 vs 4.98 ± 4.03, p <0.001), lower ratio of SUVmax (1.10 ± 0.34 vs 1.22 ± 0.27, p = 0.014), better tumor differentiation (p <0.001), and smaller tumor size (2.30 ± 1.41 vs 2.97 ± 1.71, p <0.03). The negative prediction rate was 87.08% for N2 and 80.80% for N1 disease. All patients in the BAC group were alive after the operation. The five-year survival rate of patients without BAC features was 71.2%. Conclusions: Preoperative SUVmax of PET-CT was more accurate at predicting negative N2 than N1 disease. BAC is associated with markedly better prognosis compared with invasive adenocarcinoma and may be cured with surgical resection Aggressive surgical resection is recommended even for patients with false-negative N2 disease.

Original languageEnglish
Pages (from-to)1156-1160
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume38
Issue number12
DOIs
Publication statusPublished - Dec 2012
Externally publishedYes

Fingerprint

Bronchiolo-Alveolar Adenocarcinoma
Positron-Emission Tomography
Lung
Lymph Nodes
Carcinoembryonic Antigen
Non-Small Cell Lung Carcinoma
Neoplasms
Adenocarcinoma
Survival Rate

Keywords

  • Lung cancer
  • PET-CT
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Huang, T. W., Lin, L. F., Hsieh, C. M., Cheng, Y. L., Chang, H., Tzao, C., & Lee, S. C. (2012). Positron emission tomography in bronchioloalveolar carcinoma of the lung. European Journal of Surgical Oncology, 38(12), 1156-1160. https://doi.org/10.1016/j.ejso.2012.08.020

Positron emission tomography in bronchioloalveolar carcinoma of the lung. / Huang, T. W.; Lin, L. F.; Hsieh, C. M.; Cheng, Y. L.; Chang, H.; Tzao, C.; Lee, S. C.

In: European Journal of Surgical Oncology, Vol. 38, No. 12, 12.2012, p. 1156-1160.

Research output: Contribution to journalArticle

Huang, T. W. ; Lin, L. F. ; Hsieh, C. M. ; Cheng, Y. L. ; Chang, H. ; Tzao, C. ; Lee, S. C. / Positron emission tomography in bronchioloalveolar carcinoma of the lung. In: European Journal of Surgical Oncology. 2012 ; Vol. 38, No. 12. pp. 1156-1160.
@article{673b283e608c483aa9289510b9d2a541,
title = "Positron emission tomography in bronchioloalveolar carcinoma of the lung",
abstract = "Objectives: This study assessed the maximum standard uptake value of positron emission tomography-computed tomography in patients of pulmonary adenocarcinoma with bronchioloalveolar carcinoma features and whether SUVmax correlates with pathological status, lymph node metastasis, and prognosis. Methods: We retrospectively reviewed 674 patients diagnosed with non-small-cell lung cancer between January 2002 and June 2009. Patients with clinical stage I-II disease underwent a preoperative PET-CT scan followed by anatomic resection. We reviewed the clinical features of 209 patients with an average follow-up of 87 months. Results: We analyzed clinical variables for 40 patients with BAC features and 169 patients without BAC features. Age, sex, location, and number of dissected lymph nodes, carcinoembryonic antigen level, and lymphovascular invasion had no difference between the two groups. Compared with non-BAC patients, patients with BAC features had a lower SUVmax (2.51 ± 2.02 vs 4.98 ± 4.03, p <0.001), lower ratio of SUVmax (1.10 ± 0.34 vs 1.22 ± 0.27, p = 0.014), better tumor differentiation (p <0.001), and smaller tumor size (2.30 ± 1.41 vs 2.97 ± 1.71, p <0.03). The negative prediction rate was 87.08{\%} for N2 and 80.80{\%} for N1 disease. All patients in the BAC group were alive after the operation. The five-year survival rate of patients without BAC features was 71.2{\%}. Conclusions: Preoperative SUVmax of PET-CT was more accurate at predicting negative N2 than N1 disease. BAC is associated with markedly better prognosis compared with invasive adenocarcinoma and may be cured with surgical resection Aggressive surgical resection is recommended even for patients with false-negative N2 disease.",
keywords = "Lung cancer, PET-CT, Prognosis",
author = "Huang, {T. W.} and Lin, {L. F.} and Hsieh, {C. M.} and Cheng, {Y. L.} and H. Chang and C. Tzao and Lee, {S. C.}",
year = "2012",
month = "12",
doi = "10.1016/j.ejso.2012.08.020",
language = "English",
volume = "38",
pages = "1156--1160",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Positron emission tomography in bronchioloalveolar carcinoma of the lung

AU - Huang, T. W.

AU - Lin, L. F.

AU - Hsieh, C. M.

AU - Cheng, Y. L.

AU - Chang, H.

AU - Tzao, C.

AU - Lee, S. C.

PY - 2012/12

Y1 - 2012/12

N2 - Objectives: This study assessed the maximum standard uptake value of positron emission tomography-computed tomography in patients of pulmonary adenocarcinoma with bronchioloalveolar carcinoma features and whether SUVmax correlates with pathological status, lymph node metastasis, and prognosis. Methods: We retrospectively reviewed 674 patients diagnosed with non-small-cell lung cancer between January 2002 and June 2009. Patients with clinical stage I-II disease underwent a preoperative PET-CT scan followed by anatomic resection. We reviewed the clinical features of 209 patients with an average follow-up of 87 months. Results: We analyzed clinical variables for 40 patients with BAC features and 169 patients without BAC features. Age, sex, location, and number of dissected lymph nodes, carcinoembryonic antigen level, and lymphovascular invasion had no difference between the two groups. Compared with non-BAC patients, patients with BAC features had a lower SUVmax (2.51 ± 2.02 vs 4.98 ± 4.03, p <0.001), lower ratio of SUVmax (1.10 ± 0.34 vs 1.22 ± 0.27, p = 0.014), better tumor differentiation (p <0.001), and smaller tumor size (2.30 ± 1.41 vs 2.97 ± 1.71, p <0.03). The negative prediction rate was 87.08% for N2 and 80.80% for N1 disease. All patients in the BAC group were alive after the operation. The five-year survival rate of patients without BAC features was 71.2%. Conclusions: Preoperative SUVmax of PET-CT was more accurate at predicting negative N2 than N1 disease. BAC is associated with markedly better prognosis compared with invasive adenocarcinoma and may be cured with surgical resection Aggressive surgical resection is recommended even for patients with false-negative N2 disease.

AB - Objectives: This study assessed the maximum standard uptake value of positron emission tomography-computed tomography in patients of pulmonary adenocarcinoma with bronchioloalveolar carcinoma features and whether SUVmax correlates with pathological status, lymph node metastasis, and prognosis. Methods: We retrospectively reviewed 674 patients diagnosed with non-small-cell lung cancer between January 2002 and June 2009. Patients with clinical stage I-II disease underwent a preoperative PET-CT scan followed by anatomic resection. We reviewed the clinical features of 209 patients with an average follow-up of 87 months. Results: We analyzed clinical variables for 40 patients with BAC features and 169 patients without BAC features. Age, sex, location, and number of dissected lymph nodes, carcinoembryonic antigen level, and lymphovascular invasion had no difference between the two groups. Compared with non-BAC patients, patients with BAC features had a lower SUVmax (2.51 ± 2.02 vs 4.98 ± 4.03, p <0.001), lower ratio of SUVmax (1.10 ± 0.34 vs 1.22 ± 0.27, p = 0.014), better tumor differentiation (p <0.001), and smaller tumor size (2.30 ± 1.41 vs 2.97 ± 1.71, p <0.03). The negative prediction rate was 87.08% for N2 and 80.80% for N1 disease. All patients in the BAC group were alive after the operation. The five-year survival rate of patients without BAC features was 71.2%. Conclusions: Preoperative SUVmax of PET-CT was more accurate at predicting negative N2 than N1 disease. BAC is associated with markedly better prognosis compared with invasive adenocarcinoma and may be cured with surgical resection Aggressive surgical resection is recommended even for patients with false-negative N2 disease.

KW - Lung cancer

KW - PET-CT

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84868384209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868384209&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2012.08.020

DO - 10.1016/j.ejso.2012.08.020

M3 - Article

C2 - 23017426

AN - SCOPUS:84868384209

VL - 38

SP - 1156

EP - 1160

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 12

ER -